Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Single-Tube Flow Cytometry 12-Color Combination for the Screening, Classification, and Staging of Chronic Myelomonocytic Leukemia. Correlation with NGS Molecular Data

Paula Piñero, Rocio Gonzalez, Vanesa Diaz, Elena Marin, Marina Gonzalez, Javier Lopez, Pablo Manresa, M. Carmen Garcia Hernandez, Fabian Tarin

Blood (2024) 144 (Supplement 1): 1824.

https://doi.org/10.1182/blood-2024-201371

Published: 2024

Journal Articles

Prognostic Value of Response to First-Line Hydroxyurea According to Ipset Stratification in Essential Thrombocythemia

Blood (2024) 144 (Supplement 1): 241.

https://doi.org/10.1182/blood-2024-198336

Published: 2024

Journal Articles

At-Home Allogeneic Stem Cell Transplantation: A Single Centre Experience

Ignacio Gómez-Centurión, Carmen García Menéndez, Rebeca Bailen, Paula Fernández-Caldas, Lucia Castilla Garcia, Pablo Silva, Carmen López Fresneña, Ramon García, Mi Kwon

Blood (2024) 144 (Supplement 1): 4872.

https://doi.org/10.1182/blood-2024-210530

Published: 2024

Journal Articles

Impact of Bone Marrow Evaluation Using Bone Marrow Biopsy, Flow Cytometry, and PET/CT in B-Cell Non-Hodgkin Lymphomas

José Antonio Sánchez Salas, Estela Ruiz Ruiz, Almudena Cascales Hernandez, Joaquin Gomez Espuch, Andrea Poveda Garcia, Angela Heredia Cano, Miguel Blanquer Blanquer, Maria Carmen GARCIA Garay, Antonio Jose Martinez Mellado, Alfredo Minguela Puras, Agueda Bas Bernal, Vanessa Roldan Schilling, Antonio Salar Silvestre

Blood (2024) 144 (Supplement 1): 4401.

https://doi.org/10.1182/blood-2024-208744

Published: 2024

Journal Articles

Treatment Outcomes in Unfit Patients with Newly Acute Myeloid Leukemia According to IDH1 Mutational Status: Real World Evidence from the Pethema Epidemiologic Registry

Blood (2023) 142 (Supplement 1): 4223.

https://doi.org/10.1182/blood-2023-189800

Published: 2023

Journal Articles

Real-World Effectiveness of Asciminib in Patients with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: A Global Chart Review Study of Patients Treated in the Asciminib Managed Access Program (MAP)

Dragana Milojkovic, Nicole Blijlevens, Yok-Lam Kwong, Uzma Zaidi, Fausto Castagnetti, Paolo Gallipoli, Maria Cristina Miggiano, Peter E Westerweel, Melissa Chen, M. Carmen Garcia Hernandez, William J. Kell, Pankit Vachhani, Neha Agarwal, Alessandra Colasante, Sridhar Meka, Aoife Smyth, Germano Ferreira, Jeroen J.W.M. Janssen

Blood (2023) 142 (Supplement 1): 4541.

https://doi.org/10.1182/blood-2023-181937

Published: 2023

Journal Articles

Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis

Blood (2022) 140 (Supplement 1): 826–827.

https://doi.org/10.1182/blood-2022-158669

Published: 2022

Journal Articles

Toxicity of Asciminib in Real Clinical Practice; Analysis of Side Effects and Cross-Intolerance with Tyrosine Kinase Inhibitors

Lucía Pérez-Lamas, Alejandro Luna, Concepcion Boque, María Alicia Senin, Blanca Xicoy, Pilar Giraldo, Raul Perez Lopez, Concepción Ruiz Nuño, Natalia De las Heras, Elvira Mora Casterá, Carmen Garcia-Hernandez, Adrian Segura Diaz, Juan Luis Steegmann, Patricia Velez Tenza, Fermin Sanchez-Guijo, Ana Maria Garcia-Noblejas Moya, Juan Antonio Juan Vera Goñi, Melania Moreno Vega, Alberto Alvarez-Larran, Montse Cortes, Manuel Perez Encinas, Luis Serrano, Anna Angona, Ana Rosell, Sunil Lakhwani, Mercedes Colorado, Elena Ramila, Carlos Cervero, Beatriz Cuevas, Lucia Villalon Blanco, Juan Carlos Hernandez Boluda, Antonio Paz Coll, Valle Gómez García de Soria, Maria Jose Fernández, Luis Felipe Casado, Juan Manuel Alonso-Dominguez, Maria Magdalena Anguita Arance, Patricia Carrascosa Mastell, Araceli Salamanca Cuenca, Antonio Jiménez-Velasco, María José Ramírez, Miguel López Esteban, Magdalena Sierra Pacho, Marta Santaliestra, Olga Alda Alvarez, Raquel de Paz, Valentín García Gutiérrez

Blood (2022) 140 (Supplement 1): 3925–3928.

https://doi.org/10.1182/blood-2022-167453

Published: 2022

Journal Articles

Thrombogenesis Mechanisms of High Doses of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) Compared to Tyrosine Kinase Inhibitors

Blood (2022) 140 (Supplement 1): 6730–6732.

https://doi.org/10.1182/blood-2022-163070

Published: 2022

Journal Articles

Asciminib in Real-Life Clinical Practice, Safety and Efficacy Profile in Chronic Myeloid Leukemia Pretreated Patients

Lucía Pérez-Lamas, Alejandro Luna, Concepcion Boque, Pilar Giraldo, Blanca Xicoy, Luis Felipe Casado, Fermin Sanchez-Guijo, Concepción Ruiz Nuño, Melania Moreno Vega, Alberto Alvarez-Larran, Araceli Salamanca Cuenca, Ana García-Noblejas, Ferran Vall-Llovera, Manuel Perez Encinas, Lucia Villalon, Natalia De las Heras, Sunil Lakhwani, Elena Ramila, Beatriz Cuevas, Raul Perez Lopez, Antonio Jiménez-Velasco, Ana Rosell, Angeles Escola, Maria Jose Fernández, Carmen Garcia-Hernandez, Carlos Cervero, Elvira Mora Casterá, Miguel Sagüés, Sara Suarez-Varela, Patricia Vélez, Patricia Carrascosa Mastell, Rocio Fé Bitaube, Luis Serrano, Montse Cortes, Juan Antonio Juan Vera Goñi, Juan Luis Steegmann, Juan Carlos Hernandez Boluda, Valle Gomez, Juan Manuel Alonso-Dominguez, Mercedes Colorado Araujo, Antonio Paz Coll, Valentín Garcia Gutierrez

Blood (2021) 138 (Supplement 1): 2563.

https://doi.org/10.1182/blood-2021-150813

Published: 2021

Journal Articles

Safety and Efficacy Profile of Asciminib As Treatment in Chronic Myeloid Leukemia Patients after Several Tyrosine-Kinase Inhibitors Failure

Blood (2020) 136 (Supplement 1): 49–50.

https://doi.org/10.1182/blood-2020-138690

Published: 2020

Journal Articles

Evaluation of the in Vitro Procoagulant Effect of Factor IX Concentrates in Patients on Prophylaxis with Emicizumab

Ihosvany Fernandez-Bello, María Teresa Alvarez Román, Mónica Martín, María Isabel Rivas Pollmar, Sara García Barcenilla, Carmen García Martínez, Tamara Cebanu, Paula Acuña, Raul Justo Sanz, Elena Monzón Manzano, Miguel A Canales, MD PhD, Nora Butta, PhD, Victor Jimenez-Yuste

Blood (2019) 134 (Supplement_1): 1118.

https://doi.org/10.1182/blood-2019-129983

Published: 2019

Journal Articles

Excess Mortality in Polycythemia Vera and Essential Thrombocythemia

Arturo Pereira, MD PhD, Carlos Besses Raebel, MD PhD, Juan Carlos Hernandez Boluda, MD PhD, Francisca Ferrer Marin, MD PhD, Carmen Garcia-Hernandez, MD, María Teresa Gómez-Casares, MD PhD, Manuel Pérez-Encinas, MD, María-Soledad Noya, MD, Beatriz Cuevas, MD, Gonzalo Caballero, MD, Maribel Mata, Francisco Cervantes, MD PhD, Alberto Alvarez-Larrán, MD PhD

Blood (2018) 132 (Supplement 1): 3042.

https://doi.org/10.1182/blood-2018-99-109892

Published: 2018

Journal Articles

rs2431697, a Polymorphism of Mir-146a, Is a Precozing Marker of Progression to Secondary Myelofibrosis: New Epigenetic Regulation of Jak/Stat3 Signaling

Blood (2018) 132 (Supplement 1): 3072.

https://doi.org/10.1182/blood-2018-99-119221

Published: 2018

Journal Articles

Feasibility of Treatment Discontinuation in Chronic Myeloid Leukemia in Clinical Practice in Spain: Results from a Nationwide Series of 236 Patients

Blood (2018) 132 (Supplement 1): 47.

https://doi.org/10.1182/blood-2018-99-109976

Published: 2018

Journal Articles

Primary Analysis of JUMP, a Phase 3b, Expanded-Access Study Evaluating the Safety and Efficacy of Ruxolitinib in Patients with Myelofibrosis (N = 2233)

Haifa Kathrin Al-Ali, Lynda Foltz, Giuseppe A. Palumbo, Bruno Martino, Francesca Palandri, PhD MD, Anna Marina Liberati, Philipp Le Coutre, Carmen Garcia-Hernandez, Andrey Zaritskey, Renato Tavares, Martin Griesshammer, Vikas Gupta, MD PhD, Pia Raanani, Pilar Giraldo, PhD, Catherine Bouard, Julian Perez Ronco, Ranjan Tiwari, Francesco Mannelli, Alessandro M. Vannucchi

Blood (2017) 130 (Supplement 1): 4204.

https://doi.org/10.1182/blood.V130.Suppl_1.4204.4204

Published: 2017

Journal Articles

Safety and Efficacy of Ruxolitinib for the Final Enrollment of JUMP: An Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis (N = 2233)

Lynda Foltz, MD FRCP, Giuseppe A. Palumbo, MD, Bruno Martino, MD, Francesca Palandri, MD PhD, Haifa Kathrin Al-Ali, MD, Anna Marina Liberati, MD, Philipp D. Le Coutre, MD, Alessandro M. Vannucchi, MD, Carmen Garcia-Hernandez, MD, Renato Tavares, MD, Martin Griesshammer, MD, Vikas Gupta, MD, Pia Raanani, MD, Pilar Giraldo, MD PhD, Catherine Bouard, Julian Perez Ronco, MD MBA, Sadhvi Khanna, MS, Andrey Zaritskey, MD

Blood (2016) 128 (22): 3107.

https://doi.org/10.1182/blood.V128.22.3107.3107

Published: 2016

Journal Articles

Safety and Efficacy of Bosutinib in Fourth Line Therapy of Chronic Myeloid Leukemia Patients

Valentín García-Gutiérrez, Dragana Milojkovic, María Luisa Martín Mateos, Simone Claudiani, Concepcion Boque, PhD, Luis Felipe Casado, Gloria González, Antonio Jiménez, Alejandra Martinez Trillos, Isabel Mata Vázquez, Ángel Ramírez Payer, Alberto Álvarez Larran, Elena Amutio Díez, Abelardo Bárez García, MD, Guiomar Bautista Carrascosa, Sabela Bobillo Varela, Beatriz Cuevas Ruiz, Mª Ángeles Fernández Fernández, María del Carmen García Garay, Pilar Giraldo, MD PhD, Jose María Guinea de Castro, Natalia De Las Heras Rodríguez, MD, Nuria Hernanz Soler, Ana Iglesias Pérez, José Luis López Lorenzo, Josep Maria Martí Tutusaus, MD PhD, Rolando Omar Vallansot, Fernando Ortega Rivas, Jose Manuel Puerta, Maria Jose Ramírez Sánchez, Esperanza Romero Picos, Mario Andrés Romo Collada, Ana Rosell Mas, Silvana Saavedra Gerosa, Ana Sebrango Sadia, José Tallón Pérez, Sandra Valencia, Juan Luis Steegmann, MD

Blood (2015) 126 (23): 2786.

https://doi.org/10.1182/blood.V126.23.2786.2786

Published: 2015

Journal Articles

Bosutinib Apears to be Safe, with Low Cross Intolerance, in Patients Treated in 4th Line. Results of the Spanish Compassionate Use Program

Blood (2014) 124 (21): 5523.

https://doi.org/10.1182/blood.V124.21.5523.5523

Published: 2014

Journal Articles

Association between the proliferative rate of neoplastic B cells, their maturation stage, and underlying cytogenetic abnormalities in B-cell chronic lymphoproliferative disorders: analysis of a series of 432 patients

Blood (2008) 111 (10): 5130–5141.

https://doi.org/10.1182/blood-2007-10-119289

Published: 2008

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Single-Tube Flow Cytometry 12-Color Combination for the Screening, Classification, and Staging of Chronic Myelomonocytic Leukemia. Correlation with NGS Molecular Data

Prognostic Value of Response to First-Line Hydroxyurea According to Ipset Stratification in Essential Thrombocythemia

At-Home Allogeneic Stem Cell Transplantation: A Single Centre Experience

Impact of Bone Marrow Evaluation Using Bone Marrow Biopsy, Flow Cytometry, and PET/CT in B-Cell Non-Hodgkin Lymphomas

Treatment Outcomes in Unfit Patients with Newly Acute Myeloid Leukemia According to IDH1 Mutational Status: Real World Evidence from the Pethema Epidemiologic Registry

Real-World Effectiveness of Asciminib in Patients with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: A Global Chart Review Study of Patients Treated in the Asciminib Managed Access Program (MAP)

Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis

Toxicity of Asciminib in Real Clinical Practice; Analysis of Side Effects and Cross-Intolerance with Tyrosine Kinase Inhibitors

Thrombogenesis Mechanisms of High Doses of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) Compared to Tyrosine Kinase Inhibitors

Asciminib in Real-Life Clinical Practice, Safety and Efficacy Profile in Chronic Myeloid Leukemia Pretreated Patients

Safety and Efficacy Profile of Asciminib As Treatment in Chronic Myeloid Leukemia Patients after Several Tyrosine-Kinase Inhibitors Failure

Evaluation of the in Vitro Procoagulant Effect of Factor IX Concentrates in Patients on Prophylaxis with Emicizumab

Excess Mortality in Polycythemia Vera and Essential Thrombocythemia

rs2431697, a Polymorphism of Mir-146a, Is a Precozing Marker of Progression to Secondary Myelofibrosis: New Epigenetic Regulation of Jak/Stat3 Signaling

Feasibility of Treatment Discontinuation in Chronic Myeloid Leukemia in Clinical Practice in Spain: Results from a Nationwide Series of 236 Patients

Primary Analysis of JUMP, a Phase 3b, Expanded-Access Study Evaluating the Safety and Efficacy of Ruxolitinib in Patients with Myelofibrosis (N = 2233)

Safety and Efficacy of Ruxolitinib for the Final Enrollment of JUMP: An Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis (N = 2233)

Safety and Efficacy of Bosutinib in Fourth Line Therapy of Chronic Myeloid Leukemia Patients

Bosutinib Apears to be Safe, with Low Cross Intolerance, in Patients Treated in 4th Line. Results of the Spanish Compassionate Use Program

Association between the proliferative rate of neoplastic B cells, their maturation stage, and underlying cytogenetic abnormalities in B-cell chronic lymphoproliferative disorders: analysis of a series of 432 patients

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only